Important Notice
After the disclosure of the 2024 annual report, there is a risk of delisting for the company, as the audited total profit, net profit, and net profit after deducting non-recurring gains and losses for the year 2024 are all negative, and the revenue after deductions is below 300 million yuan. According to Article 9.3.12 of the "Shenzhen Stock Exchange Stock Listing Rules (2024 Revision)," the company's stock will be delisted from the Shenzhen Stock Exchange. This annual report summary is derived from the full annual report. To fully understand the company's operational results, financial status, and future development plans, investors should carefully read the full annual report published in designated media by the China Securities Regulatory Commission. All directors attended the board meeting to review this report.
Non-standard Audit Opinion
□ Applicable ☒ Not Applicable
Profit Distribution Plan
The board's resolution regarding the profit distribution plan for the reporting period or the capital reserve transfer to increase share capital □ Applicable ☒ Not Applicable
The company plans not to distribute cash dividends, issue bonus shares, or transfer capital reserves to increase share capital. The preferred stock profit distribution plan approved by the board is □ Applicable ☒ Not Applicable
Company Overview
- Company Profile
- Stock Abbreviation: *ST Longjin
- Stock Code: 002750
- Stock Exchange: Shenzhen Stock Exchange
- Previous Stock Abbreviation (if any): Longjin Pharmaceutical
- Contact Person and Information:
- Secretary of the Board: Li Yahe
- Securities Affairs Representative: Ning Bo
- Office Address: No. 789, Lanmao Road, Majinpu Street Office, High-tech Zone, Kunming City, Yunnan Province
- Fax: 0871-68520855
- Phone: 0871-64179595
- Email: kmljyy@vip.sina.com